Mick Hitchcock is a scientist and a researcher who sees the future through a lens that has research providing the answers to the problems that confront us.
Together with former Bristol colleague John Martin, he developed Viread, approved by the FDA in 2001 a once-daily pill to treat HIV. Subsequently, the pair developed Atripla, approved in 2006 as the first single-tablet regimen for treatment of HIV that includes the active component of Viread and two other drugs. Ease of use made it a popular choice for physicians and patients.
More recently, the company launched Sovaldi and Harvoni, Hepatitis C treatments that can essentially cure most patients with few side effects.
This is a kid-friendly event. All are invited to attend.